Abstract
We measured plasma sex hormone-binding globulin (SHBG), corticosteroid-binding globulin
(CBG), and total cortisol, and calculated free plasma cortisol in 1 137 subjects attending
a hospital outpatient lipid disorders clinic to investigate whether or not these analytes
correlated with the degree of insulin resistance and the presence of the metabolic
syndrome. In both males and females, plasma SHBG correlated inversely with anthropometric
measures and with fasting glucose, insulin, insulin resistance, and triglycerides,
and positively with HDL-cholesterol. However, in males with the metabolic syndrome,
unlike females, the relationship between SHBG, some anthropometric measures, fasting
glucose, insulin, and HDL-cholesterol were lost, which suggests that in males SHBG
may not co-cluster with other components of the metabolic syndrome. In males and males
with the metabolic syndrome, total plasma cortisol and calculated plasma free cortisol
correlated positively with fasting glucose. Corticosteroid-binding globulin correlated
inversely with percentage body fat and positively with HDL-cholesterol in males with
and without the metabolic syndrome. CBG correlated negatively with age in both sexes.
Overall, the results confirm the finding that SHBG is a marker of insulin resistance
in males and females and that SHBG is associated with fasting triglycerides in males
with the metabolic syndrome. Importantly, SHBG could be considered a stronger component
of the metabolic syndrome in females than in males. However, the aetiological role
of CBG and cortisol in insulin resistance is uncertain, although in males, cortisol
and CBG could be subtly related to the degree of insulin resistance.
Key words
SHBG - CBG - cortisol - free cortisol - plasma - insulin resistance - glucose - insulin
- metabolic syndrome
References
1
Katsuki A, Sumida Y, Murashima S, Fujii M, Ito K, Tsuchihashi K, Murata K, Yano Y,
Shima T.
Acute and chronic regulation of serum sex hormone-binding globulin levels by male
noninsulin-dependent diabetes mellitus patients.
J Clin Endocrinol Metab.
1996;
81
2515-2519
2
Muller M, Grobbee DE, Tonkelaar den I, Lamberts SWJ, Schouw van der YT.
Endogenous sex hormones and metabolic syndrome in aging men.
J Clin Endocrinol Metab.
2005;
90
2618-2623
3
Lewis JG, Shand BI, Elder PA, Scott RS.
Plasma sex hormone-binding globulin rather than corticosteroid-binding globulin is
a marker of insulin resistance in obese adult males.
Diabet Obes Metab.
2004;
6
259-283
4
Tchernof A, Despres JP.
Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women.
Horm Metab Res.
2000;
32
526-536
5
Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen T-P, Salonen R, Rauramaa R,
Salonen JT.
Sex hormones, inflammation and the metabolic syndrome: a population-based study.
Eur J Endocrinol.
2003;
149
601-608
6
Reed MJ, Cheng RW, Simmonds M, Richmond W, James VH.
Dietary lipids: an additional regulator of plasma levels of sex hormone-binding globulin.
J Clin Endocrinol Metab.
1987;
64
1083-1085
7
Plymate SR, Matej LA, Jones RE, Friedl KE.
Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2)
cell line by insulin and prolactin.
J Clin Endocrinol Metab.
1988;
67
460-464
8
Maggio M, Lauretani F, Basaria S, Ceda GP, Bandinelli S, Metter EJ, Bos AJ, Rugiero C,
Ceresini G, Paolisso G, Artoni A, Valenti G, Guralnik JM, Ferrucci L.
Sex hormone-binding globulin levels across the adult lifespan in women: the role of
body mass index and fasting insulin.
J Endocrinol Invest.
2008;
31
597-601
9
Jayagopal V, Kilpatrick ES, Jennings PE, Holding S, Hepburn DA, Atkin SL.
The biological variation of sex hormone-binding globulin in Type 2 diabetes.
Diabetes Care.
2004;
27
278-280
10
McElduff A, Hitchman, R, McElduff P.
Is sex hormone-binding globulin associated with glucose tolerance?.
Diabetic Medicine.
2005;
23
306-312
11
Haffner SM, Katz MS, Stern MP, Dunn JF.
Relationship of sex hormone-binding globulin to overall adiposity and body fat distribution
in a biethnic population.
Int J Obes.
1989;
13
1-9
12
Crave JC, Lejeune H, Brebant C, Baret C, Pugeat M.
Differential effects of insulin and insulin-like growth factor 1 on the production
of plasma steroid-binding globulins by human hepatoblastoma-derived (Hep G2) cells.
J Clin Endocrinol Metab.
1995;
80
1283-1289
13
Fernández-Real J-M, Pugeat M, Emptoz-Bonneton A, Ricart W.
Study of the effect of changing glucose, insulin, and insulin-like growth factor-I
levels on serum corticosteroid-binding globulin in lean, obese, and obese subjects
with glucose intolerance.
Metabolism.
2001;
50
1248-1252
14
Fernández-Real J-M, Pugeat M, Grasa M, Broch M, Vendrell J, Brun J, Ricart W.
Serum corticosteroid-binding globulin concentration and Insulin Resistance Syndrome:
A population study.
J Clin Endocrinol Metab.
2002;
87
4680-4690
15
Lewis JG, Möpert B, Shand BI, Doogue MP, Soule SG, Frampton CM, Elder PA.
Plasma variation of corticosteroid-binding globulin and sex hormone-binding globulin.
Horm Metab Res.
2006;
38
241-245
16
Lewis JG, Shand BI, Frampton CM, Elder PA, Scott RS.
Plasma levels of sex hormone-binding globulin, corticosteroid-binding globulin and
cortisol in overweight subjects who develop impaired fasting glucose: a 3-year prospective
study.
Horm Metab Res.
2009;
41
255-259
17
Lewis JG, Longley NJ, Elder PA.
Monoclonal antibodies to human sex hormone-binding globulin (SHBG): Characterization
and use in a simple enzyme-linked immunosorbent assay (ELISA) of SHBG in plasma.
Steroids.
1999;
64
259-265
18
Lewis JG, Lewis MG, Elder PA.
An enzyme-linked immunosorbent assay for corticosteroid-binding globulin using monoclonal
and polyclonal antibodies: decline in CBG following synthetic ACTH.
Clin Chim Acta.
2003;
328
121-128
19
Lewis JG, Manley L, Whitlow JC, Elder PA.
Production of a monoclonal antibody to cortisol: application to a direct enzyme-linked
immunosorbent assay of plasma.
Steroids.
1992;
57
82-85
20
Coolens J-L, Van Baelen H, Heyns W.
Clinical use of unbound plasma cortisol as calculated from total cortisol and corticosteroid-binding
globulin.
J Steroid Biochem.
1987;
26
197-202
21
Levy JC, Matthews DR, Hermans MP.
Correct homeostasis model assessment (HOMA) evaluation uses the computer program.
Diabetes Care.
1998;
21
2191-2192
22
Alberti KG, Zimmet PZ.
Definition, diagnosis and classification of diabetes mellitus and its complications.
Part 1: diagnosis and classification of diabetes mellitus provisional report of a
WHO consultation.
Diabet Med.
1998;
15
539-553
23
Executive summary of the third report of the national Cholesterol Education Program
(NECP) expert panel on detection, evaluation, and treatment of high blood cholesterol
in adults (Adult Treatment Panel III).
JAMA.
2001;
285
2486-2497
24
Muller M, den Tonkelaar I, Thijssen JHH, Grobbee DE, van der Schouw YT.
Endogenous sex hormones in men aged 40-80 years.
Eur J Endocrinol.
2003;
149
583-589
25
Weinberg ME, Manson JE, Buring JE, Cook NR, Seely, EW, Ridker PM, Rexrode KM.
Low sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal
women.
Metab Clin Exp.
2006;
55
1473-1480
26
Haffner SM, Valdez RA, Morales PA, Hazuda HP, Stern MP.
Decreased sex hormone-binding globulin predicts noninsulin-dependent diabetes mellitus
in women but not in men.
J Clin Endocrinol Metab.
1993;
77
56-60
27
Selva DM, Hogeveen KN, Innis SM, Hammond GL.
Monosaccharide-induced lipogenesis regulates the human hepatic sex-hormone-binding
globulin gene.
J Clin Invest.
2007;
117
3979-3987
28
Hautanen A.
Synthesis and regulation of sex hormone-binding globulin in obesity.
Int J Obes Relat Metab Disord.
2000;
24
S64-S70
29
Chubb SAP, Hyde Z, Almeida OP, Flicker L, Norman PE, Jamrozik K, Hankey GJ, Yeap BB.
Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome
than lower testosterone in older men: the Health in Men Study.
Eur J Endocrinol.
2008;
158
785-792
30
Bataille V, Perret B, Evans A, Amouyel P, Arveiler D, Ducimetière P, Bard J-M, Ferrières J.
Sex hormone-binding globulin is a major determinant of the lipid profile: the PRIME
study.
Atherosclerosis.
2005;
179
369-373
31
Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen T-P, Valkonen V-P, Salonen R,
Salonen JT.
Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes
in middle-aged men.
Diabetes Care.
2004;
27
1036-1041
32
Pasquali R, Vicennati V.
Steroids and the metabolic syndrome.
J Steroid Biochem Mol Biol.
2008;
109
258-265
33
Fernández-Real J-M, Pugeat M, López-Bermejo A, Bornet H, Ricart W.
Corticosteroid-binding globulin affects the relationship between circulating adiponectin
and cortisol in men and women.
Metab Clin Exper.
2005;
54
584-589
34
Araki T, Emoto M, Konishi T, Ikuno Y, Lee E, Teramura M, Motoyama K, Yokoyama H, Mori K,
Koyama H, Shoji T, Nishizawa Y.
Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin
levels in type 2 diabetes mellitus.
Metab Clin Exper.
2009;
58
143-148
35
Schulze MB, Rimm EB, Shai IS, Rifai N, Hu FB.
Relationship between adiponectin and glycemic control, blood lipids, and inflammatory
markers in men with type 2 diabetes.
Diabetes Care.
2004;
27
1680-1687
36
Reynolds RM, Walker BR.
Can cortisol predict the future in obesity?.
Clin Endocrinol.
2007;
67
1-2
37
Holt HB, Wild SH, Postle AD, Zhang J, Koster G, Umpleby M, Shojaee-Moradie F, Dewbury K,
Wood PJ, Phillips DI, Byrne CD.
Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver
in middle-aged men.
Diabetologia.
2007;
50
1024-1032
38
Wang M.
The role of glucocorticoid action in the pathophysiology of the metabolic syndrome.
Nutr Metab.
2005;
2
3-16
39
Walker BR.
Glucocorticoids and cardiovascular disease.
Eur J Endocrinol.
2007;
157
545-559
40
Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler UH, Kuhl H.
Effect of four different oral contraceptives on various sex hormones and serum-binding
globulins.
Contraception.
2003;
67
25-32
41
Santini SA, Carrozza C, Lulli P, Zuppi C, Tonolo GC, Musumeci S.
Atorvastatin treatment does not affect gonal or adrenal hormones in type 2 diabetes
patients with mild to moderate hypercholesterolemia.
J Artheroscler Thromb.
2003;
10
160-164
42
Hacihanefioglu B, Somunkiran A, Mahmutoglu I, Sercelik A, Toptani S, Kervancioglu E.
Effect of hypertension therapy with the angiotensin-converting enzyme inihibitor lisinopril
on hyperandrogenism in women with polycystic ovary syndrome.
Fertil Steril.
2002;
77
526-528
43
Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, Pasquali R.
Effect of flutamide and metformin administered alone or in combination in dieting
obese women with polycystic ovary syndrome.
Clin Endocrinol.
2004;
60
241-249
44
Stroud LR, Solomon C, Shenassa E, Papandonatos G, Niaura R, Lipsitt LP, LeWinn K,
Buka SL.
Long-term stability of maternal prenatal steroid hormones from the National Collaborative
Perinatal Project: Still valid after all these years.
Psychoneuroendocrinol.
2007;
32
140-150
Correspondence
J. G. Lewis
Department of Clinical Biochemistry
Canterbury Health Laboratories
P. O. Box 151
Christchurch
New Zealand
Telefon: +64 3 3640 877
Fax: +64 3 3640 889
eMail: john.lewis@cdhb.govt.nz